We were missing JZ on claim after claim
Oncology Billing Services
One missing modifier can
erase an oncology billing claim
A single chemotherapy vial can cost thousands of dollars. Medicare wants to know exactly how much was given and how much was discarded. Miss the modifier confirming zero waste, and the claim is erased entirely. Miss the one for real waste, and the practice absorbs a cost it was owed. Our oncology billing services get that distinction right, on every drug claim.
96%avg. net collection rate across TruCare clients



See your numbers
Or call (760) 589-6611
Results across TruCare clients
96%
>95%
−37%
−38%
Why oncology practices choose our oncology medical billing services
Rated 4.8 / 5
Verified client reviews
What we handle, from authorization to the drug claim
View all servicesWe get your oncologists and your infusion staff enrolled
Provider enrollmentPECOS upkeepRevalidation
The drug costs more than the visit. The modifier decides who pays for the difference.
Six places oncology revenue goes missing
The zero-waste modifier was left off
Medicare requires explicit confirmation that nothing was discarded from a single-dose vial. Leaving this off is treated as a reporting failure, not a minor omission, and the claim is denied.
Real waste was never reported
When a dose does not use the full vial, the discarded amount is separately billable. Not reporting it means the practice absorbs a cost Medicare would have paid.
An outdated 340B modifier was still in use
Program identifiers for discount-acquired drugs have changed. A claim using the retired version does not match current system requirements.
J-code units did not match the actual dose
Billing based on the vial size instead of what was actually administered creates a mismatch between the claim and the clinical record.
Treatment started before authorization was confirmed
Beginning an infusion before a pathway-dependent authorization comes through risks the entire claim, not just a portion of it.
Clinical trial routine costs were billed inconsistently
Billing a trial patient’s routine visits the same as a non-trial patient, without the coverage distinction that actually applies, creates both compliance risk and lost revenue.
Rated on the platforms that matter



Our service offerings
Every part of a modern oncology practice
Chemotherapy and infusion administration
High-cost drug billing
340B drug program billing
Immunotherapy and targeted therapy
Oral oncolytics
Prior authorization and pathway compliance
Clinical trial routine cost billing
Radiation oncology, briefly
What actually makes this work
Billers who read the drug record, not just the order
Authorization checked against the pathway before scheduling
No disruption to how your infusion suite already runs
What actually causes oncology claims to fail
Curious what your denials are actually costing you?
Request a billing auditThe recurring six:

Missing zero-waste confirmation
Waste never separately reported
Outdated program modifier used
Dose and billed units mismatched
Treatment started without confirmed authorization
Clinical trial billing not separated correctly
The details that decide whether a drug claim actually pays
Walk through your coding with usThe ones that matter most:
96401–96549
Chemotherapy and infusion administration
Billed by route and complexity, push versus infusion, with specific sequencing rules for an initial service versus additional or sequential drugs in the same encounter. These codes have not changed structurally in recent years.
We connect to the EHR you already use
Check for your system
Deep integrations with all EHRs
TruCare connects seamlessly with your existing workflows — no switching required.
What actually moved for this specialty this year
Chemotherapy administration codes did not change
The underlying CPT code structure for chemotherapy and infusion administration remained the same for 2026. Anything claiming new administration codes this year is describing something that did not happen.
Site-neutral payment expanded to drug administration
CMS finalized an expansion of its site-neutral payment policy to cover drug administration services furnished in excepted off-campus, provider-based departments, directly affecting hospital-affiliated oncology practices.
Radiation treatment delivery codes were consolidated
Three codes, 77385, 77386, and 77014, were deleted and consolidated into 77402, 77407, and 77412, a structural change specific to radiation oncology billing.
The 340B identification modifier changed before this year, and confusion still lingers
The modifier once used to flag 340B-acquired drugs was discontinued effective January 1, 2025, replaced entirely by the current identifier, though some billing guidance still incorrectly references the retired version.
Skin substitutes were reclassified, removing them from waste reporting entirely
Effective January 1, 2026, non-biologic skin substitutes were reclassified as incident-to supplies rather than drugs, meaning JW and JZ reporting no longer applies to them at all.
JZ enforcement continued to generate denials for practices that overlook it
Mandatory since mid-2023, the zero-waste modifier continues to be one of the single most common sources of avoidable denials for practices still adjusting their workflow around it.
Someone has to track a modifier system this precise
A reporting requirement this specific, applied to drugs this expensive, is not something to leave to habit or memory.
In-house vs. outsourced
What one biller cannot track on claims this expensive
| The question | One in-house biller | TruCare |
|---|---|---|
| Waste reporting | Inconsistent or skipped | Applied correctly on every single-dose vial claim |
| 340B identification | Sometimes using an outdated modifier | Always current |
| Dose versus billed units | Vial size billed by habit | Matched to actual administered dose |
| Prior authorization and pathways | Requested after scheduling | Confirmed before treatment begins |
| Clinical trial billing | Billed the same as standard care | Separated correctly by coverage rule |
| Radiation oncology coding | Learned as claims fail | Current with the latest code consolidation |
| Cost shape | Salary, benefits, training, software | A percentage of collections, so it scales with volume |
| Staff absence | Billing slows on high-dollar claims | Coverage is handled without disruption |
| Regulatory change | Discovered through a denial | Tracked and built into process ahead of time |
| Visibility | A report assembled on request | Live, by drug, by modifier, and by regimen |
Hover a state to see coverage
Where we serve
Oncology billing in every state
Drug waste reporting
340B billing
Prior authorization and pathways
Clinical trial billing
Multi-state enrollment
A named account contact
Who we bill every day
Medicare Part B
Medicare Advantage
Medicaid and managed Medicaid
BCBS and Anthem
Centene family
Other
We bill whatever plans your practice is contracted with. If you are not contracted yet, TruCred handles the enrollment.
Oncology billing saver guide
A practice collecting $2.05 million saves up to $22,015 a year by outsourcing to TruCare
| In-house billing | With TruCare | Annual saving | |
|---|---|---|---|
| Dedicated billing staff | $73,060 | $0 | $73,060 |
| Billing software and clearinghouse | Varies | Included | — |
| Training, turnover, and coverage | Varies | Included | — |
| TruCare fee (from 2.49% of collections) | — | $51,045 | — |
| Total annual cost | $73,060 | $51,045 | $22,015 |
Example: a practice collecting $2.05 million a year with one full-time biller, at TruCare’s starting rate of 2.49%. Biller cost uses the BLS May 2025 median wage for medical records specialists ($51,140), with benefits at 30% of total compensation. Software and training costs vary by practice and are not counted. We do not replace your front desk, we take the claims work off it. Larger oncology practices, where collections are driven heavily by high-cost drug volume, are quoted on volume rather than at the starting rate, so a bigger practice should not scale this example up.
Want this run on your own numbers?
Talk to an oncology billing expertWhat a practice gains once every modifier is actually checked
“We assumed our denials were about the drugs themselves being questioned. They were not. They were about a reporting requirement we did not fully understand, applied to drugs expensive enough that the mistake was never small. Once someone actually fixed how we reported waste, the difference showed up immediately.”
Dr. Anand Krishnamurthy
Medical oncologist, community oncology practice